Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of inhaled steroids

Trial Profile

Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of inhaled steroids

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Fluticasone propionate; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Biomarker; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Apr 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov
    • 01 Apr 2009 Planned end date (Dec 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top